Healthcare

Subcutaneous injection is considered a standard method for the delivery of medication into a patient’s body. To facilitate subcutaneous injection, subcutaneous injection ports are used. Subcutaneous injection ports are sterile medication delivery device. Subcutaneous injection ports consists of a silicone injection membrane on a hard base. Through subcutaneous injection port physician prescribed medications can be directly injected into the subcutaneous tissue using a standard needle and syringe, an injection pen, or other manual injection device. Subcutaneous injection port is a device that cannot be used with an injection pump. Furthermore, subcutaneous injection ports are also used for multiple subcutaneous injections for a period of up to 72 hours. Subcutaneous injection port avoids the repeated needle punctures of the skin. This device is widely used for patients who require prolonged central venous access. A subcutaneous injection port is generally a disposable device usually inserted into the skin for a period of up to 5 days. Insulin is injected through a syringe into subcutaneous injection port. Medicines are directly injected through the resealable septum at the top of the device. The needle of the syringe is placed above the surface of the skin whereas the medication is delivered through the soft cannula. A subcutaneous injection port consists of a build in inserter, which give users a virtually painless application.  A subcutaneous injection port is usually used with an intrathecal or epidural catheter. Subcutaneous injection ports have low infection rate, but require suitable expertise for their insertion.

The global subcutaneous injection ports market is expected to witness a significant growth over the forecast period due to rising prevalence of cancer and diabetes across the globe. Increasing investment of manufacturers in the development of subcutaneous injection port is further driving the growth of the global subcutaneous injection ports market. Furthermore, over the past decade, more patient-friendly devices have enhanced the demand for subcutaneous injection ports. However, lack of focus on health expenditure, declining reimbursements and others factors are the hindrance of the global subcutaneous injection ports market.

The global market for subcutaneous injection port is segmented on basis of product type, end user and geography.

• Based on Product Type, the global subcutaneous injection ports market is segmented into:
  • I-Port
  • Insuflon
• Based on End User, the global subcutaneous injection ports market is segmented into:
  • Hospitals
  • Clinics
  • Home Care Settings

On the basis of geography, the global subcutaneous injection ports market is segmented into six key regions viz. North America, Latin America, Europe, Asia Pacific excluding China, China and the Middle East & Africa. North America will continue to dominate the global subcutaneous injection ports market due to the availability of advanced technologies. Europe is expected to hold the second large market share in the global subcutaneous injection ports market. Asia Pacific is also one of the fast-growing regions in the global subcutaneous injection ports market due to high incidence of diabetes in low-income countries. Moreover, the Middle East and Africa and Latin America are expected to show slow growth in the global subcutaneous injection ports market due to delayed introduction of the product in these regions.

Examples of some of the key players present in the global subcutaneous injection ports market are Medtronic MiniMed, Inc., Applied Medical Technology Ltd, Unomedical a/s and others.

The report covers exhaustive analysis on:

• Subcutaneous Injection Ports Market Segments
• Subcutaneous Injection Ports Market Dynamics
• Historical Actual Market Size, 2013 - 2017
• Subcutaneous Injection Ports Market Size & Forecast 2018 to 2026
• Subcutaneous Injection Ports Market Current Trends/Issues/Challenges
• Competition & Companies involved
• Subcutaneous Injection Ports Market Drivers and Restraints

Regional analysis includes

• North America
• Latin America
• Europe
• Asia Pacific excluding China
• China
• Middle East & Africa

Report Highlights:

• Shifting Industry dynamics
• In-depth market segmentation
• Historical, current and projected industry size Recent industry trends
• Key Competition landscape
• Strategies of key players and product offerings
• Potential and niche segments/regions exhibiting promising growth
• A neutral perspective towards market performance

Silicone gel-filled breast implants consist of an outer shell made of silicone and filled with silicone gel. The silicone gel is a bit more like natural breast tissue. Silicone gel-filled breast implants are available in different sizes with smooth or textured shells. Generally, silicone gel-filled breast implants are approved for breast augmentation and breast reconstruction surgeries. FDA-approved silicone gel-filled breast implant is for breast augmentation in women aged 22 or older and for breast reconstruction in women of any age. Moreover, the implants are also used in revision surgeries which improve or correct the result of an original surgery. Usually, breast implants are not lifetime devices. Adverse and frequent complications experienced by breast implant patients include reoperation, capsular contracture, and implant removal. Some of the other complications include wrinkling, implant rupture, asymmetry, pain, scarring, and infection. Breast implantation surgery increases the probability of being diagnosed with anaplastic large cell lymphoma (ALCL). MRI is considered to be an effective method for detecting silent rupture of silicone gel-filled breast implants.

According to FDA, there are five silicone gel-filled breast implants been approved, namely Allergan Natrelle (approved in November 2006), Allergan Natrelle 410 Highly Cohesive Anatomically Shaped Silicone-Filled Breast Implants (approved in February 2013), Mentor MemoryGel (approved in November 2006), Mentor MemoryShape (approved in June 2013) and Sientra’s Silicone Gel Breast Implants (approved in March 2012).

According to a journal published in the U.S., it was estimated that around 93,083 breast reconstruction procedures and 296,203 breast augmentation procedures were performed in 2010. In 2015, according to the estimates of the American Society for Aesthetic Plastic Surgery, approximately 47.9% of breast implant procedures were undertaken by women belonging to the age group of 19–34 years in the U.S.

The growth of the global silicone gel-filled breast implant market is driven by increasing prevalence and incidence of breast cancer in the global population. For instance, according to the research conducted in 2017, it is estimated that 1 in every 8 (nearly 12%) women will develop invasive breast cancer over the course of the lifetime in the U.S. alone. Furthermore, population drifting towards aesthetic appearance and increasing disposable income are also driving the growth of the global silicone gel-filled breast implant market. However, the high cost related to breast implantation surgeries and lack of skilled personnel are the major factors hampering the growth of the global silicone gel-filled breast implant market. Most of the cases of breast implants cause health problems as women with implants need additional surgeries to replace or remove their implant. This hampers the growth of the silicone gel-filled breast implant market. In addition, it is also estimated that one in four women who get breast implants will require additional surgery. The cost of removing or replacing breast implants can be higher than the cost of getting implants in the first place.

The global market for silicone-gel filled breast implant is segmented on basis of application, end user and geography.

• Segmentation by Application
  • Breast Augmentation
  • Breast Reconstruction
• Segmentation by End User
  • Hospitals
  • Clinics
  • Cosmetic Clinics
  • Ambulatory Surgical Centers

On the basis of geography, the global silicone gel-filled breast implant market is segmented into six key regions viz. North America, Latin America, Europe, Asia Pacific excluding China, China and the Middle East & Africa. The North America silicone gel-filled breast implant market is expected to hold the large share in the global market, followed by Europe, due to the increasing prevalence and incidence of breast cancer. Moreover, increasing number of cancer surgeries coupled with the presence of sophisticated healthcare infrastructure is also boosting the growth of the silicone gel-filled breast implant market. The silicone gel-filled breast implant market in the Asia Pacific region is expected to grow at a higher rate due to the presence of large population base, and favorable reimbursement scenario. However, the market for silicone gel-filled breast implant in regions such as Latin America, and the Middle East and Africa are estimated to show a stagnant growth over the forecast period. Latin America is expected to gain future opportunities due to the increasing medical tourism in countries such as Brazil, Mexico, and Argentina.

Examples of some of the key players present in the global silicone gel-filled breast implant market are Allergan plc, Mentor Worldwide LLC, Sientra, Inc. and others.

The report covers exhaustive analysis on:

• Silicone Gel-Filled Breast Implant Market Segments
• Silicone Gel-Filled Breast Implant Market Dynamics
• Historical Actual Market Size, 2013 - 2017
• Silicone Gel-Filled Breast Implant Market Size & Forecast 2017 to 2026
• Silicone Gel-Filled Breast Implant Market Current Trends/Issues/Challenges
• Competition & Companies involved
• Silicone Gel-Filled Breast Implant Market Drivers and Restraints

Regional analysis includes

• North America
• Latin America
• Europe
• Asia Pacific excluding China
• China
• Middle East & Africa

Report Highlights:

• Shifting Industry dynamics
• In-depth market segmentation
• Historical, current and projected industry size Recent industry trends
• Key Competition landscape
• Strategies of key players and product offerings
• Potential and niche segments/regions exhibiting promising growth
• A neutral perspective towards market performance

During the past few years, the global burden of pediatric HIV infection is becoming a challenge for the healthcare industry. According to the World Health Organization, it is estimated that around 3.2 million people were living with HIV infection at the end of 2013. Majority of children acquire HIV infection from their HIV-infected mothers during pregnancy, breastfeeding or birth. Effective treatments can reduce the risk of mother-to-child HIV transmission. However, in most of the resource-limited countries where the burden of HIV is high, the treatment for pediatric HIV infection is still not widely available. Pediatric HIV infection causes immunologic deterioration, opportunistic infections, and cancers. Diagnosis of pediatric HIV infection includes viral antibodies and virologic nucleic acid amplification tests. Viral antibodies are given to children above 18 months whereas virologic nucleic acid amplification tests (such as PCR) are performed in children less than 18 months. Combination of antiretroviral drugs is given for the treatment of pediatric HIV infection. The general pathophysiology of pediatric HIV infection is similar to that in adults however, the clinical presentations, the method of infection and treatments often differ.  

Worldwide, each year, about 150,000 more children are infected (7 to 10% of all new infections) with HIV infection, and about 110,000 children die. Some of the risk factors related to the vertical transmission of HIV infection in children include high plasma viral RNA concentrations, seroconversion during pregnancy or breastfeeding, advanced maternal disease, and low maternal peripheral CD4+ T-cell counts. The most common signs of pediatric HIV infection not receiving ART include generalized lymphadenopathy, splenomegaly, oral candidiasis, hepatomegaly, CNS disease, failure to thrive, recurrent bacteremia, lymphoid interstitial pneumonitis, hepatitis, nephropathy, and others.

The market for pediatric HIV infection treatment is primarily driven by increasing prevalence of HIV infection in children. Active involvement of national and international government bodies to promote the research on HIV infection treatment drugs is responsible to drive the growth of the market during the forecast period. Moreover, increasing private-public partnerships for the research and development activities and increasing healthcare expenditure are also some of the factors driving the growth of the pediatric HIV infection treatment market. However, unavailability of treatment options in the underdeveloped countries can be the factor which can hamper the growth of global pediatric HIV infection treatment market. Moreover, the limited number of treatment options with a very high cost of branded drugs in various regions have impeded the growth of the global pediatric HIV infection treatment market.

The global market for pediatric HIV infection treatment is segmented on basis of HIV infection types, treatment, distribution channel and geography:

• Segmentation by Type
  • Not symptomatic
  • Mildly symptomatic
  • Moderately symptomatic
  • Severely symptomatic
• Segmentation by Treatment
  • Antiretroviral (ARV) drugs
    • Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
    • Protease Inhibitor (PI)
    • Integrase Strand Transfer Inhibitor (INSTI)
    • Others
  • Supportive care
• Segmentation by Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Drugstore
  • e-commerce

On the basis of geography, global pediatric HIV infection treatment market is segmented into six key regions viz. North America, Latin America, Europe, Asia Pacific excluding China, China and Middle East & Africa. North America is expected to witness faster revenue growth in comparison with markets in other regions owing to higher infection rate amongst children and a large number of pediatric population suffering from HIV infection. Asia Pacific is also one of the fast growing regions in the global pediatric HIV infection treatment market due to high involvement of government-non-government bodies in promoting HIV infection treatment campaigns. Moreover, the Middle East and Africa and Latin America are expected to show less growth in the global pediatric HIV infection treatment market due to delayed introduction of treatment therapies in the regions.

Examples of some of the key players present in the global pediatric HIV infection treatment market are GlaxoSmithKline plc., F. Hoffmann-La Roche Ltd, ViiV Healthcare, Camber Pharmaceuticals, Inc., Johnson & Johnson Services, Inc., Apotex Inc., and others.

The report covers exhaustive analysis on:

• Pediatric HIV Infection Treatment Market Segments
• Pediatric HIV Infection Treatment Market Dynamics
• Historical Actual Market Size, 2012 - 2016
• Pediatric HIV Infection Treatment Market Size & Forecast 2016 to 2024
• Pediatric HIV Infection Treatment Market Current Trends/Issues/Challenges
• Competition & Companies involved
• Pediatric HIV Infection Treatment Market Drivers and Restraints

Regional analysis includes

• North America
• Latin America
• Europe
• Asia Pacific
• Middle East & Africa

Report Highlights:

• Shifting Industry dynamics
• In-depth market segmentation
• Historical, current and projected industry size Recent industry trends
• Key Competition landscape
• Strategies of key players and product offerings
• Potential and niche segments/regions exhibiting promising growth
• A neutral perspective towards market performance

An artificial eye improves the appearance of people who have lost an eye due to injury or disease. An artificial eye is also known as prosthetic eye or glass eye. Implantation of an artificial eye is preferred or recommended after an eye is removed surgically due to disease or damage. The implanted artificial eye supports the proper eyelid functioning. Injury, glaucoma, infection inside the eye and eye tumors are some of the reasons for removing the natural eye and implanting an artificial one. After the placement of natural eye with an artificial eye, a person will no longer have a vision in that eye. Artificial eyes cannot restore the vision of the person but it fills the cavity of the eye socket and serves as a cosmetic enhancement. Artificial eyes are generally made of an acrylic plastic polymer called polymethyl methacrylate (PMMA). In addition, silicone polymers are also used to make artificial eyes. The shape of an artificial eye is like a shell. An artificial eye can move but often not as briskly as other healthy eyes. Artificial eyes are made from digital technology and have become so close to looking like real eyes.

According to the Society for the Prevention of Blindness, it is estimated that around 10,000 to 12,000 people per year lose and eye. Out of which around 50% or more eyes losses are caused by an accident.

The global artificial eyes market is expected to see remarkable growth in the forecast period due to increasing number demand by a large number of patient population. Furthermore, an encouraging sign can be observed in the market with changing consumer trends. Others factors such as increasing prevalence and incidence of eye-related disease, changing lifestyle pattern, increasing accident cases are the factors which are fueling the growth of the global artificial eyes market. However, factors like tough competition among the key players, and side effects of common medication are the major factors hampering the growth of the global artificial eyes market.

The global market for artificial eyes is segmented on basis of types of artificial eyes, shell types, end user and geography:

• Segmentation by Type
  • Moulded Prosthesis
  • Cosmetic Shell
• Segmentation by Shell Type
  • Single Shell
  • Double shell
• Segmentation by End User
  • Hospitals
  • Ambulatory Surgical Centers
  • Clinics
  • Ophthalmology Surgery Center

Based on types, the global artificial eyes market is segmented into moulded prosthesis and cosmetic shell. The moulded prosthesis is an artificial eye which is specifically made based on the impression taken from the socket of an individual. A moulded eye provides the closest possible match to a real eye. Whereas, cosmetic shell artificial eyes completely covers the existing eye.

On the basis of geography, the global artificial eyes market is segmented into six key regions viz. North America, Latin America, Europe, Asia Pacific excluding China, China and Middle East & Africa. North America is expected to lead the artificial eyes market due to product innovations, the presence of leading players, favorable reimbursement policies and high adoption of artificial eye surgeries. Manufacturers are targeting developed markets due to rising incidence of eye diseases in this developing countries. Europe is the second leading market for artificial eyes market due to development activities, increased healthcare spending per person, and government support. The Asia Pacific market is also expected to grow at the highest growth rate due to a large patient pool, and product awareness due to medical conferences. These factors are likely to drive the market growth of artificial eyes market during the forecast period globally. However, Latin America and Middle East Africa are expected to mark sluggish growth over the forecast period.

Examples of some of the key players present in the global artificial eyes market are Advanced Artificial Eyes, Midwest Eye Laboratories, Inc., Erickson's Eyes, F.AD. MÜLLER SÖHNE OHG, Nikolaus Kerbl and others. Mergers, acquisition, expansion, strategic collaborations, and technology play vital roles in the growth of the artificial eyes market.

The report covers exhaustive analysis on:

• Artificial Eyes Market Segments
• Artificial Eyes Market Dynamics
• Historical Actual Market Size, 2013 - 2017
• Artificial Eyes Market Size & Forecast 2017 to 2026
• Artificial Eyes Market Current Trends/Issues/Challenges
• Competition & Companies involved
• Artificial Eyes Market Drivers and Restraints

Regional analysis includes

• North America
• Latin America
• Europe
• Asia Pacific excluding China
• China
• Middle East & Africa

Report Highlights:

• Shifting Industry dynamics
• In-depth market segmentation
• Historical, current and projected industry size Recent industry trends
• Key Competition landscape
• Strategies of key players and product offerings
• Potential and niche segments/regions exhibiting promising growth
• A neutral perspective towards market performance

Tubal obstruction devices are micro-insert devices used for prevention of pregnancy and maturation of egg in ovaries. Tubal obstruction devices are used in birth control and working two principles namely tissue ingrowth and mechanical obstruction. Tubal obstruction devices is a minimally invasive method for birth control. Mostly these devices are made up of polyethylene, ceramic, nylon, and silicone. The first FDA approved tubal occlusion device is Essure permanent birth control system. In recent times, it has become popular because of its minimally invasive nature with the high degree of effectiveness. This device consists of two coils namely: inner coil and the outer coil. Inner coil is made up of polyethylene terephthalate fibers and stainless steel and outer is made up of nitinol. It is used for permanent birth control by inducing benign tissue ingrowth. The success rate of this device is 83% to 94.1% and it offers advantages like avoidance of incisions, general anesthesia, and general narcotics.  

Tubal Obstruction Devices Market: Drivers and Restraints

During past decade, tubal obstruction devices have become increasingly popular due to the fact that they can achieve either permanent or reversible conception. Increasing demand for permanent birth control procedure boosts the growth of tubal obstruction devices market. Rising population in emerging countries like India & China etc. pose a significant threat to economies of the country. In order to control the population of the countries, governments have taken many initiatives to raise awareness among the general population. Along with government initiatives, increasing knowledge among the general population regarding growing concerns about overpopulation has a significant effect on the market. Tubal obstruction device offers more benefits over conventional techniques because it’s minimally invasive with fewer side effects. The rapid advancement of technologies enabled tubal obstruction devices to comply more with patient personal requirements. Improved patient compliance also boosted the growth of the market. All these factors fueled the growth of the tubal obstruction devices market.

The lack of substantial data regarding large patient pool is expected to limit the growth of tubal obstruction devices market.

Tubal Obstruction Devices Market: Segmentation

Segmentation based on End User

• Hospitals
• Clinics
• Ambulatory Surgical Centers

Tubal Obstruction Devices Market: Market Overview

Global Tubal Obstruction Devices Market has witnessed a robust growth due to increasing demand for devices. They are minimally invasive with minimum side effects and it is more advantageous over conventional surgery. Tubal Obstruction Devices Market has a presence of a few players which have a huge market share in global market operating at the country level. There are huge opportunities for the untapped markets across the world due to potential benefits of Tubal Obstruction Devices Market. The key players in the Tubal Obstruction Devices Market are mainly focused on R&D to accelerate the development due to a limited number of manufacturers. The future of Tubal Obstruction Devices Market anticipated with double CAGR during forecasting period.

Tubal Obstruction Devices Market: Region-wise Overview

Global Tubal Obstruction Devices Market is segmented into the following regions - North America, Latin America, Western Europe, Eastern Europe, Asia Pacific and the Middle East & Africa. North America is dominant in the global tubal obstruction devices market mainly due to the increasing penetration. In North America, the USA is dominating the market due to high adoption among end users. Economic conditions in the APAC region are set to drive the tubal obstruction devices market to new heights. Europe and APAC tubal obstruction devices markets are the fastest growing regions due to increasing awareness. Growth in the Middle East & African region is considerably less when compared to the other regions. However, North America would maintain its position in the tubal obstruction devices market, though, we are anticipating developed economies such as Australia to have the highest growth rate in Tubal Obstruction Devices Market.

Tubal Obstruction Devices Market: Key Participants

The key participants in Tubal Obstruction Devices Market are Bayer AG, IdeaConnection Ltd., and others. The companies are mainly focusing on collaboration and partnership to keep up the pace of the competition and to develop new products.

The report covers exhaustive analysis on:

• Market Segments
• Market Dynamics
• Historical Actual Market Size, 2013 – 2017
• Market Size & Forecast, 2018 to 2026
• Supply & Demand Value Chain
• Market Current Trends/Issues/Challenges
• Competition & Companies involved
• Technology
• Value Chain
• Aircraft Refurbishing Market Drivers and Restraints

Regional analysis for Market includes

• North America
• Latin America
• Europe
• Asia Pacific & Japan
• Middle East & Africa

Report Highlights:

• Shifting Industry dynamics
• In-depth market segmentation
• Historical, current and projected industry size, recent industry trends
• Key Competition landscape
• Strategies for key players and product offerings
• Potential and niche segments/regions exhibiting promising growth
• A neutral perspective towards market performance

The endorectal balloon is single-use, inflatable, disposable, non-powered rectal device used in immobilization of prostate in patients. These devices are intended to be used in patients undergoing radiotherapy and it can be used in all stages. The endorectal balloon is traditionally used in the treatment of prostate cancer with benefits like consistent rectal filing & prostate stability. The endorectal balloon is used to move posterior wall away from the prostate and helps in reduction of radiation to the rectum and mucosal wall. It can be well tolerated in over 95% of patients. While, they are contraindicated in patients with severe hemorrhoids, anal fissures, peri-rectal/peri-anal abscess, rectal fistula, anal canal stricture and prior low anterior resection. When it comes to technical information, endorectal balloon contains two radiopaque markers and they are located in the catheter shaft. It is equipped with a valve and it controls inflation and deflation. Advantages of the endorectal balloon include infra-fraction motion control, limit radiation dose to the wall, controls late toxicity, increases visibility and increases patient compliance.

Endorectal Balloon Market: Drivers and Restraints

Increasing demand for intensity modulated radiotherapy by decreasing toxicity of rectum accelerates the growth of endorectal balloon market. Prostate infraction motion is the major concern in radiotherapy, regardless of the type of therapy. Typically, prostate motion is associated with rectal fillings and bladder function. Along with this, advancement of technologies enabled usage of proton therapy for prostate cancer treatment. It allows dose distribution to the target area and controls the dose escalation. But, dose escalation of a dose is also associated with toxicities. To avoid dose escalations in proton therapies, the endorectal balloon is used to control the dose escalations, prostate movement and increases the rectal filling without disturbing normal physiological functions. The endorectal balloon is used to improve the target localization, decreases anorectal toxicities. Emerging evidence of endorectal balloon advantages in reducing toxicities are expected to boost the growth of the market. All these factors fueled the burgeoning growth of endorectal balloon market. Further, the advantages of the endorectal balloon over the conventional methods accelerated the growth of the market.

The lack of substantial evidence regarding the benefits of the endorectal balloon in the large patient pool has limited the growth of endorectal balloon market.

Endorectal Balloon Market: Segmentation

Segmentation based on End User

• Hospitals
• Clinics
• Radiotherapy Centers

Endorectal Balloon Market: Market Overview

Global Endorectal Balloon market has witnessed a robust growth due to increasing demand for devices. They are more advantageous over conventional methods in treating prostate cancer. It controls dose escalations and reduces the rectum toxicity. Endorectal Balloon market has a presence of a few players which have a huge market share in the global market operating at the country level. There are huge opportunities for the untapped markets across the world due to potential benefits of Endorectal Balloon. The key players in the Endorectal Balloon market are mainly focused on R&D to accelerate the development due to a limited number of manufactures. The future of Endorectal Balloon market anticipated with double CAGR during forecasting period.

Endorectal Balloon Market: Region-wise Overview

Global endorectal balloon market is segmented into the following regions - North America, Latin America, Western Europe, Eastern Europe, Asia Pacific and the Middle East & Africa. North America is dominant in the global endorectal balloon market mainly due to the increasing prevalence of prostate cancer. In North America, particularly the USA is dominating due to high adoption among end users. Economic conditions in the APAC region are set to drive the endorectal balloon market to new heights. Europe and APAC endorectal balloon markets are fastest growing regions due to increasing awareness. Growth in the Middle East and African region is considerably less when compared to the other regions. However, North America would maintain its position in the endorectal balloon market, though, we are anticipating developed economies such as Australia to have the highest growth rate in the endorectal balloon market.

Endorectal Balloon Market: Key Participants

The key participants in Endorectal Balloon Market are QLRAD, Bionix, and others. The companies are mainly focusing on collaborations and partnerships to keep up the pace of the competition and to develop new products.

The report covers exhaustive analysis on:

• Market Segments
• Market Dynamics
• Historical Actual Market Size, 2013 – 2017
• Market Size & Forecast, 2018 to 2026
• Supply & Demand Value Chain
• Market Current Trends/Issues/Challenges
• Competition & Companies involved
• Technology
• Value Chain
• Aircraft Refurbishing Market Drivers and Restraints

Regional analysis for Market includes

• North America
• Latin America
• Europe
• Asia Pacific & Japan
• Middle East & Africa

Report Highlights:

• Shifting Industry dynamics
• In-depth market segmentation
• Historical, current and projected industry size, recent industry trends
• Key Competition landscape
• Strategies for key players and product offerings
• Potential and niche segments/regions exhibiting promising growth
• A neutral perspective towards market performance

Alexandrite laser uses alexandrite crystals as the source of the laser. Laser (light amplification by stimulated emission of radiation) works on the principle of light emission and it is focused on particular body region to destroy diseased cells. Alexandrite laser is used to produce the specific wavelength of infrared light. It produces wavelength of 755 nm and it can also produce high-intensity beam in short pulses. Alexandrite laser works on the principle of light emission by laser and it is converted into heat energy. This process is called photothermolysis and heat energy is used to treat the wide variety of disease conditions. US FDA has approved alexandrite laser for various skin disorders. Alexandrite laser is used to treat vascular lesions, pigmented lesions, hair removal and tattoo removal. In case of vascular lesions, light pulses of alexandrite laser target red pigments of a body. In case of pigmented lesions, alexandrite laser target melanin at variable depth on or in the skin. In hair removal cases, pulse durations of 2 to 20 milliseconds are used to targets hair follicles, causing the hair to fall out and reduce the further growth.

Alexandrite laser treatment Market: Drivers and Restraints

Alexandrite laser treatment is considered as effective for all hair and skin types and it increases the scope of device application. The light emitted by alexandrite laser device is absorbed easily by the skin and is considered as the most effective method for treating skin disorders. It is considered as safe and effective due to fewer frequency wavelengths used to treat skin conditions. The market is primarily driven by a few key factors such as the inclination towards non-invasive or minimally invasive techniques like alexandrite laser for treating skin disorders. The market is likely to grow owing to the increasing awareness regarding alexandrite laser treatment procedures, and the equal effectiveness of non-invasive surgeries is expected to fuel the growth of alexandrite laser treatment market. The rising demand for such therapies has also evolved due to the limited post-surgical care requirements, which are among the factors that are expected to aid the growth of alexandrite laser treatment market over the forecast years. The increasing effectiveness of alexandrite laser treatment for pigmentation removal from the skin is growing in demand globally. All these factors act as a driver of the burgeoning growth of the alexandrite laser treatment market.

Lack of awareness regarding the alexandrite laser treatment in emerging economies is expected to restrain the growth of the alexandrite laser treatment market.

Alexandrite laser treatment Market: Segmentation

Segmentation based on Indication

• Vascular Lesions
• Pigmented Lesions
• Hair Removal
• Others

Segmentation based on End User

• Hospitals
• Clinics
• Others

Alexandrite laser treatment Market: Market Overview

Global alexandrite laser treatment market has witnessed a robust growth due to increasing demand for devices. They are minimally invasive with minimum side effects and it is more advantageous compared to conventional techniques. Alexandrite laser treatment market has a presence of a few players which have a huge market share in global market operating at the country level. There are huge opportunities for the untapped markets across the world due to potential benefits of alexandrite laser treatment market. The key players in the alexandrite laser treatment market are mainly focused on R&D to accelerate the development due to a limited number of manufactures. The future of alexandrite laser treatment market anticipated with double growth rate during forecasting period.

Alexandrite laser treatment Market: Region-wise Overview

Global Alexandrite laser treatment Market is segmented into the following regions - North America, Latin America, Western Europe, Eastern Europe, Asia Pacific and the Middle East & Africa. North America is dominant in the global alexandrite laser treatment market mainly due to the increasing penetration. In North America, the USA is dominating the market due to high adoption among end users. Economic conditions in the APAC region are set to drive the alexandrite laser treatment market to new heights. Europe and APAC alexandrite laser treatment markets are fastest growing regions due to increasing awareness. Growth in the Middle East and African region is considerably less when compared to the other regions. However, North America is expected to maintain its position in the alexandrite laser treatment market, though, we are anticipating developed economies such as Australia to have the highest growth rate in alexandrite laser treatment market.

Alexandrite laser treatment Market: Key Participants

The key participants in Alexandrite laser treatment market are Light Age Incorporated, Cynosure, Inc. and others. The companies are mainly focusing on collaboration and partnership to keep up the pace of the competition and to develop new products.

The report covers exhaustive analysis on:

• Market Segments
• Market Dynamics
• Historical Actual Market Size, 2013 – 2017
• Market Size & Forecast, 2018 to 2026
• Supply & Demand Value Chain
• Market Current Trends/Issues/Challenges
• Competition & Companies involved
• Technology
• Value Chain
• Aircraft Refurbishing Market Drivers and Restraints

Regional analysis for Market includes

• North America
• Latin America
• Europe
• Asia Pacific & Japan
• Middle East & Africa

Report Highlights:

• Shifting Industry dynamics
• In-depth market segmentation
• Historical, current and projected industry size, recent industry trends
• Key Competition landscape
• Strategies for key players and product offerings
• Potential and niche segments/regions exhibiting promising growth
• A neutral perspective towards market performance

Recent years has been observed with the advancements in surgical intervention for treating spinal deformity. Current surgical techniques for scoliosis treatment yields positive results but limits postoperative spinal motion due to the spine fusion. For overcoming these negative consequences, there exists the development of techniques for scoliosis correction without fusion. There has been an increasing traction of fusionless scoliosis surgery via minimally invasive techniques among the spine surgeons. Fusionless scoliosis is a less invasive surgical procedure that has been followed by many surgeons for the past 10 years. This involves the placement of titanium pedicle screws and cord for correcting the curvature of scoliosis. Fusionless scoliosis surgery is usually recommended for patients having a curvature of over 40 degrees. As compared with the fusion surgery, fusionless scoliosis surgery aims to support spine growth and movement. The conventional treatment also diminishes growth in height as lengthening proceeds. There are currently two techniques being used for fusionless scoliosis surgery: Vertebral body stapling and vertebral body tethering. Vertebral body stapling is employed for smaller and more flexible curves in younger patients whereas, vertebral body stapling is performed in patients having growth reaming in flexible thoracic curves measuring 35°-70° and lumbar curves measuring 30°-70°.

Fusionless scoliosis surgery is mostly performed in the children and adolescents. There is still a need for the development of new techniques and instrumentation as well as long-term follow-up of results for driving the market growth of fusionless scoliosis surgery.

Fusionless Scoliosis Surgery market: Drivers & Restraints

Several advantages of fusionless scoliosis surgery such as less invasiveness, flexibility and more comfort level promotes the market growth of fusionless scoliosis surgery. Several research studies have come up with promising benefits form the technique which further supports the market growth. This new technology and the associated devices are currently not approved by FDA and there also lacks the supportive long-term evidences which however restricts the market growth.

Fusionless Scoliosis Surgery market: Segmentation

By Technology:

• Vertebral Body Stapling
• Vertebral Body Tethering

By Age Group:

• Pediatric
• Adolescents

By End Users:

• Hospitals
• Ambulatory Surgical Centers

The management of complex spinal deformity is a huge challenge for spine surgeons. Research is still going on to develop novel procedures for treating scoliosis without fusion and overcoming the limitations of traditional treatment methods. Fusionless scoliosis surgery recommends numerous opportunities for the treatment of spine deformities. After the product approval, the market is expected to boost over the forecast period. There also exists opportunity for the market players to develop innovative products and solutions in a cost-effective range. This new technique is effective in correcting scoliotic deformity as well as restoring the spinal growth. Fusionless scoliosis surgery is used only by a handful of skilled surgeons across the United States to treat scoliosis.

Geographically, the market for fusionless Scoliosis Surgery can be segmented into five regions, North America, Latin America, Europe, Asia Pacific and Middle East & Africa. North America dominates the global fusionless scoliosis surgery market owing to the robust healthcare infrastructure and adoption of the technology at several treatment centers. Apart from the North America region, the market for this treatment is not much performed but a huge growth rate can be observed in other regions over the globe. Western Europe represent the highest growth rate after North America owing to the availability of skilled professionals in the region, higher per capita income and factorable reimbursement scenario. This is followed by the Asia-Pacific market because of the increasing investment in improving healthcare facilities and increasing privatization of hospitals having world class infrastructure. Latin America followed by MEA represents the lowest growth rate over the forecast period in the fusionless scoliosis surgery market due to poor healthcare infrastructure, lack of skilled professionals as well as poor accessibility of medical facilities in the region.

There are various centers globally providing the option of fusionless scoliosis surgery. Some of them includes Shriners Hospitals for Children, MU Healthcare, NYU Langone Hospitals, ScoliSmart Clinics, Paley Institute, Children's Spine Foundation and others.

The report covers exhaustive analysis on:

• Fusionless Scoliosis Surgery Market Segments
• Fusionless Scoliosis Surgery Market Dynamics
• Fusionless Scoliosis Surgery Historical Market Size
• Fusionless Scoliosis Surgery Market Size & Forecast
• Fusionless Scoliosis Surgery Market Current Trends/Issues/Challenges
• Fusionless Scoliosis Surgery Competition & Companies involved
• Fusionless Scoliosis Surgery Market Drivers and Restraints

Regional analysis includes:

• North America
• Latin America
• Europe
• Asia Pacific Excluding China
• China
• Middle East & Africa

Report Highlights:

• Shifting Industry dynamics
• In-depth market segmentation
• Historical, current and projected industry size, recent industry trends
• Key Competition landscape
• Strategies of key players and product offerings
• Potential and niche segments/regions exhibiting promising growth
• A neutral perspective towards market performance

Nowadays, obesity is seen as a serious health concern which leads to several other health problems. One in three adults in the U.S. is suffering from the problem. Diet Pills are the medications used to lose weight and slim down along with the diet and exercise. With the increasing trend of losing weight and becoming fit, there is a rising demand for these medications. These medications don’t replace the healthy eating habits or physical exercise for losing weight. Diet pills may improve person’s health by loosening their weight and thus lowering blood sugar, blood pressure, and triglycerides. These diet pills work by increasing body metabolism, blocking your body from absorbing fat, increasing fat burning and reducing appetite. Some of the diet pills contain a stimulant medication and thus are classified as controlled substances by U.S. Drug Enforcement Agency. Researchers are currently studying several new compounds to identify safer and more effective approach to treat the problem of obesity in patients. Some of the FDA approved medications include orlistat, lorcaserin, phentermine-topiramate, naltroxine-bupropion, liraglutide etc. These diet pills have the capability to reduce 5% to 10% more of their initial weight when used as part of diet or exercise plan over the year. Several factors are considered before going on to the diet pills such as body mass index, severity of obesity and other health-related problems.

There are a variety of diet pills available in the market as over the counter and as prescribed drugs. Prescription diet pills are an option for patients having serious health risks of high blood pressure, diabetes or high cholesterol problem and are not able to control their weight with proper diet and exercise alone. Many diet pills in the market are proven to work. However, some of them are just placebo which may harm the body and do a scam of hundreds of dollars over time.

Diet Pills Market: Drivers & Restraints

The factors driving the diet pills market include the increasing incidences of high blood pressure, type 2 diabetes, or high cholesterol. Ongoing clinical trials for novel medications also support the market growth over the forecast period. In addition, increasing health awareness is also fuelling the growth of the diet pills market. Several factors restraint the market growth of diet pills such as the associated cost, unpleasant side effects. Also, many of the diet pills don’t always work for everyone which may also limit the overall market growth.

Diet Pills market: Segmentation

By Product Type:

• Prescription Based Drugs
• Over the Counter Drugs
• Herbal Supplements

By Application

• Metabolism Raising Pills
• Fat Blocking Pills
• Appetite Controlling Pills
• Others

By Distribution channel

• Hospital Pharmacy
• Retail Pharmacy
• Drug Stores

These diet pills are available as prescription as well as non-prescription drugs. Very few proven choices are available in the OTC medications for effective weight loss. Dietary supplements or herbal medications have not been studied adequately for their effectiveness or safety.  There exists opportunity for the market players to launch innovative products in the market. Marketing campaigns also play an important role in promoting new drugs and gaining maximum market share. Weight loss is a multi-billion dollar industry and represents a great opportunity for existing as well as new players to enter the market.

Geographically, the market for Diet Pills can be segmented into five regions, North America, Latin America, Europe, Asia Pacific and Middle East & Africa. North America owns the largest market share in the global diet pills market owing to the increasing obesity problem in the region, high awareness among the population, advanced healthcare facilities and favorable reimbursement scenario. This is followed by the European market with EU5 leading the market share due to the easy access to healthcare facilities, ongoing research activities for novel medications as well as availability of different medications types. Asia-Pacific is also expected to have significant growth rate over the forecast period owing to the increasing concerns for health improvements, rising trend of slim and fit body and due to the rising problems associated with obesity. Latin America followed by MEA is anticipated to have a lower market share over the globe due to the poor healthcare facilities, limited consumption of diet pills and lesser concerns for the health problems.

Some of the service providers in the Diet Pills include Cheplapharm, Arena Pharmaceuticals GmbH, GlaxoSmithKline Pharmaceuticals Ltd., Iovate  Health Sciences Inc., Zoller Laboratories, Cortislim, Nanjing Chang'ao Pharmaceutical Co., Vivus, Inc., Orexigen Therapeutics, Inc., Novo Nordisk A/S and others.

The report covers exhaustive analysis on:

• Diet Pills Market Segments
• Diet Pills Market Dynamics
• Diet Pills Historical Market Size
• Diet Pills Market Size & Forecast
• Diet Pills Market Current Trends/Issues/Challenges
• Diet Pills Competition & Companies involved
• Diet Pills Market Drivers and Restraints

Regional analysis includes:

• North America
• Latin America
• Europe
• Asia Pacific Excluding China
• China
• Middle East & Africa

Report Highlights:

• Shifting Industry dynamics
• In-depth market segmentation
• Historical, current and projected industry size, recent industry trends
• Key Competition landscape
• Strategies of key players and product offerings
• Potential and niche segments/regions exhibiting promising growth
• A neutral perspective towards market performance

The presence of biomaterials in orthopaedic surgery leads to high risk of developing deep infections. Adhesion of bacteria to the biomaterials and the production of a biofilm is of a major concern. Antibiotic-loaded Bone Cement is the pre-fabricated cement which passes certain regulations and is approved by FDA. Antibiotic-loaded bone cement was developed in view of the infections occurring in the orthopaedic surgery. This concept was first introduced in 1970. This is considered only as a support strategy in preventing the onset of infections and not the solution of bacterial prevention. The antibiotic selection is also a fundamental issue for the preparation of antibiotic-loaded bone cement. The antibiotic selected should be a broad spectrum having a low percentage of resistant species. The most regularly used antibiotics in the development of antibiotic-loaded bone cement include gentamycin, tobramycin and vancomycin. These antibiotics can be used alone or in combination. The effectiveness of antibiotic-loaded bone cement is hugely dependent on the choice of antibiotics and their proper mixing of antibiotics with the cement. The addition of antibiotics may play a role in weakening the structure and the mechanical properties of the cement. Many studies demonstrate the antibacterial effectiveness of antibiotic-loaded bone cement for the treatment of deep infections following hip and knee arthroplasty.

Antibiotics used for the preparation of bone cement is in the powder form for better integration with cement as well as lesser interference with the physical properties of the cement. The antibiotic dosage also varies depending on the use for which the cement is intended to use. An ideal antibiotic-loaded bone cement must not affect the normal bone graft characteristics of biocompatibility, bioresorbability, osteoconductivity, osteoinductivity, structural similarity, easy to use, and cost-effectiveness.

Antibiotic-loaded Bone Cement market: Drivers & Restraints

Growth in the development of synthetic materials and their acceptance fuels the market growth of antibiotic-loaded bone cement. Furthermore, continuous growth in the orthobiologics market, rising geriatric population, increasing public awareness and continuous R&D also supports the market growth. Various key developments such as product advancements and launches, mergers and acquisitions by the market players in the orthobiologics market also drive the market growth in antibiotic-loaded bone cement market. However, stringent regulations may obstruct the growth of antibiotic-loaded bone cement market. Inadequate reimbursement policies for bone grafting may also restrict the market growth. Along with this, a recent publication by the FDA questioned about the role of antibiotic-loaded bone cement spacers for the treatment of periprosthetic joint infection which may further hamper the market growth.

Antibiotic-loaded Bone Cement market: Segmentation

By Loaded Antibody Type:

• Tobramycin
• Gentamicin
• Vancomycin
• Others

By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Mail Order Pharmacies
• Drug Stores

For reducing bone infections, several strategies have been adopted in the last few years such as stringent and efficient antiseptic operative procedures and systemic antibiotic prophylaxis. The rate of infections has observed a significant reduction from 5–10% to approximately 1-2% during the last twenty years. Among these procedures, the use of antibiotic enriched bone cement is widely used. There exist several issues which are still controversial regarding the use of antibiotic-loaded bone cement such as bacterial adhesion, antibiotic resistance as well as modification in the mechanical properties of the bone cement.

Geographically, the market for antibiotic-loaded bone cement can be segmented into five regions, North America, Latin America, Europe, Asia Pacific and Middle East & Africa. North America dominates the global antibiotic-loaded bone cement market owing to the advanced bone grafting procedures in the region and favorable reimbursement scenario. Europe represents the next leading market with Germany, Italy, U.K. and France holding the major share of antibiotic-loaded bone cement market. However, Asia-Pacific represents the highest growth rate in the coming years due to the increasing access to healthcare facilities and improving healthcare infrastructure. MEA represents the least market share globally in the antibiotic-loaded bone cement market and is projected to remain same over the forecast period.

Some of the players in the Antibiotic-loaded Bone Cement market includes Stryker Corporation, Zimmer Biomet, Tecres s.p.a., DePuy Synthes, Teknimed, Exactech, Inc., Heraeus Holding and others.

The report covers exhaustive analysis on:

• Antibiotic-loaded Bone Cement Market Segments
• Antibiotic-loaded Bone Cement Market Dynamics
• Antibiotic-loaded Bone Cement Historical Market Size
• Antibiotic-loaded Bone Cement Market Size & Forecast
• Antibiotic-loaded Bone Cement Market Current Trends/Issues/Challenges
• Antibiotic-loaded Bone Cement Competition & Companies involved
• Antibiotic-loaded Bone Cement Market Drivers and Restraints

Regional analysis includes:

• North America
• Latin America
• Europe
• Asia Pacific Excluding China
• China
• Middle East & Africa

Report Highlights:

• Shifting Industry dynamics
• In-depth market segmentation
• Historical, current and projected industry size, recent industry trends
• Key Competition landscape
• Strategies of key players and product offerings
• Potential and niche segments/regions exhibiting promising growth
• A neutral perspective towards market performance